Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer

<p>Figure S7 page2</p>

Saved in:

书目详细资料
主要作者:	Craig M. Goodwin (14955973) (author)
其他作者:	Andrew M. Waters (14953065) (author), Jennifer E. Klomp (14961282) (author), Sehrish Javaid (14961285) (author), Kirsten L. Bryant (14955976) (author), Clint A. Stalnecker (14955952) (author), Kristina Drizyte-Miller (14961288) (author), Bjoern Papke (14961291) (author), Runying Yang (14961294) (author), Amber M. Amparo (14961297) (author), Irem Ozkan-Dagliyan (14961300) (author), Elisa Baldelli (14961303) (author), Valerie Calvert (14961306) (author), Mariaelena Pierobon (14961309) (author), Jessica A. Sorrentino (14961312) (author), Andrew P. Beelen (14961315) (author), Natalie Bublitz (14961318) (author), Mareen Lüthen (14961321) (author), Kris C. Wood (14961324) (author), Emanuel F. Petricoin (14961327) (author), Christine Sers (12163648) (author), Autumn J. McRee (14961330) (author), Adrienne D. Cox (14953077) (author), Channing J. Der (14961333) (author)
出版:	2025
主题:	Cancer Cancer Biology Molecular and Cellular Biology Cell Cycle CDKs and CDK inhibitors Cell Signaling Guanine nucleotide binding proteins and effectors DNA Damage and Repair DNA damage Oncogenes & Tumor Suppressors Kras Oncogenes Rb and family
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
由: Juliana Navarro-Yepes (17079059)
出版: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
由: Katrina M. Lappin (9340394)
出版: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
由: Katrina M. Lappin (9340394)
出版: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
由: Katrina M. Lappin (9340394)
出版: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
由: Katrina M. Lappin (9340394)
出版: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
由: Sami Belhadj (15052341)
出版: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
由: Min Wei (16918572)
出版: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
由: Min Wei (16918572)
出版: (2025)

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
由: Koichi Tomoshige (15304682)
出版: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
由: Long Jiang (14956159)
出版: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
由: Long Jiang (14956159)
出版: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
由: Long Jiang (14956159)
出版: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
由: Lenka Stolarova (16547259)
出版: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
由: Lenka Stolarova (16547259)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_c5lh17acatto8qf03e5ubr4i13